関連する実験動画
Updated: May 13, 2026
08:54
An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
Published on: July 20, 2014
Srcによるp27のリン酸化は,サイクリンE-Cdk2の抑制を調節する
Isabel Chu1, Jun Sun, Angel Arnaout
1Braman Family Breast Cancer Institute of the University of Miami Sylvester Comprehensive Cancer Center and Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Cell
|January 27, 2007
まとめ
腫瘍性キナーゼSrcはp27の安定性を低下させ,細胞サイクル進行を促進する. Srcを阻害するとp27レベルが上昇し,乳がんにおけるタモキシフェンの感受性を回復させる可能性がある.
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- 細胞サイクル規則 細胞サイクル規則
背景:
- p27Kip1は,G1細胞サイクル段階の重要な調節体である.
- 腫瘍性キナーゼSrcは,がんの進行に作用する.
研究 の 目的:
- p27の安定性と機能を調節するSrcの役割を調査する.
- 乳がんにおけるSrcを標的とした治療の可能性を調査する.
主な方法:
- Srcによるp27のリン酸化部位分析
- サイクリンE-Cdk2複合体によるインビトロキナーゼアッセイ.
- Src過剰発現細胞と抑制細胞におけるp27濃度の分析.
- 人間の乳がんのサンプルにおける相関性研究.
- Src阻害に対するタモキシフェンの感受性の評価.
主要な成果:
- Srcはチロシン74と88でp27をリン酸化し,その安定性を低下させます.
- Srcの活動は,p27がサイクリンE-Cdk2.2を阻害する能力を低下させる.
- Src過剰発現はp27タンパク質分解を加速し,Src阻害剤はp27の安定性を高める.
- Srcの活性化は,乳がんにおけるp27濃度の低下と相関しています.
- Srcの阻害は,抵抗性細胞系におけるタモキシフェンの感受性を回復させます.
結論:
- Src媒介によるp27のリン酸化は,細胞サイクル進行を促進し,乳がんに寄与する.
- Srcを阻害剤で標的化することは,特にタモキシフェン耐性症例において,乳がんの有効な治療戦略である可能性があります.
関連する概念動画
01:45Positive Regulator Molecules
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
01:23Negative Regulator Molecules
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
02:39Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
00:50Anaphase Promoting Complex
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...